Table 1.

Summary of clinical trials of sitafloxacin used in the present analysis

Study no.	Subject description	Dosage	Number of subjects/patients	Number of serum samples	Reference
DU6859-01	Healthy male subjects (phase I)	25, 50, 100, or 200 mg, single dose	24	310	[3, 4]
DU6859-01, 02 DU6859a-03	Healthy male subjects (phase I)	50 or 100 mg, twice daily, and 100 mg, three times daily, 7 days	18	535	[4, 16]
DU6859a-19	Elderly patients with chronic respiratory tract disease (clinical pharmacology)	50 or 100 mg, single dose	10	50	[16]
DU6859a-28	Healthy male elderly or nonelderly subjects (clinical pharmacology)	100 mg, single dose	11	101	[6]
DU6859a-37	Renal-impaired subjects (clinical pharmacology)	50 mg, single dose	12	148	[5]
DU6859a-44	Patients with respiratory tract infection (phase III, PK–PD study)	50 or 100 mg, twice daily, 7 days	137	354	[15]